Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients.
van den Hurk K, Balint B, Toomey S, O'Leary PC, Unwin L, Sheahan K, McDermott EW, Murphy I, van den Oord JJ, Rafferty M, FitzGerald DM, Moran J, Cummins R, MacEneaney O, Kay EW, O'Brien CP, Finn SP, Heffron CC, Murphy M, Yela R, Power DG, Regan PJ, McDermott CM, O'Keeffe A, Orosz Z, Donnellan PP, Crown JP, Hennessy BT, Gallagher WM. van den Hurk K, et al. Among authors: donnellan pp. Melanoma Res. 2015 Jun;25(3):189-99. doi: 10.1097/CMR.0000000000000149. Melanoma Res. 2015. PMID: 25746038
Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries.
Porta C, Levy A, Hawkins R, Castellano D, Bellmunt J, Nathan P, McDermott R, Wagstaff J, Donnellan P, McCaffrey J, Vekeman F, Neary MP, Diaz J, Mehmud F, Duh MS. Porta C, et al. Among authors: donnellan p. Cancer Med. 2014 Dec;3(6):1517-26. doi: 10.1002/cam4.302. Epub 2014 Jul 18. Cancer Med. 2014. PMID: 25045157 Free PMC article.
A review of sentinel lymph node biopsy for thin melanoma.
Joyce KM, McInerney NM, Joyce CW, Jones DM, Hussey AJ, Donnellan P, Kerin MJ, Kelly JL, Regan PJ. Joyce KM, et al. Among authors: donnellan p. Ir J Med Sci. 2015 Mar;184(1):119-23. doi: 10.1007/s11845-014-1221-1. Epub 2014 Nov 1. Ir J Med Sci. 2015. PMID: 25366817 Review.
An assessment of histological margins and recurrence of melanoma in situ.
Joyce KM, Joyce CW, Jones DM, Donnellan P, Hussey AJ, Regan PJ, Kelly JL. Joyce KM, et al. Among authors: donnellan p. Plast Reconstr Surg Glob Open. 2015 Mar 6;3(2):e301. doi: 10.1097/GOX.0000000000000272. eCollection 2015 Feb. Plast Reconstr Surg Glob Open. 2015. PMID: 25750840 Free PMC article.
Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study.
Roncolato FT, Joly F, O'Connell R, Lanceley A, Hilpert F, Buizen L, Okamoto A, Aotani E, Pignata S, Donnellan P, Oza A, Avall-Lundqvist E, Berek JS, Heitz F, Feeney A, Berton-Rigaud D, Stockler MR, King M, Friedlander M; GCIG Symptom Benefit group. Roncolato FT, et al. Among authors: donnellan p. Oncologist. 2017 Sep;22(9):1117-1124. doi: 10.1634/theoncologist.2017-0047. Epub 2017 Jun 8. Oncologist. 2017. PMID: 28596446 Free PMC article.
Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy - The GCIG symptom benefit study (SBS).
Roncolato FT, O'Connell RL, Joly F, Lanceley A, Hilpert F, Buizen L, Okamoto A, Aotani E, Salutari V, Donnellan P, Oza A, Avall-Lundqvist E, Berek J, Fehm T, Ledermann J, Roemer-Becuwe C, Stockler MR, King MT, Friedlander ML. Roncolato FT, et al. Among authors: donnellan p. Gynecol Oncol. 2020 Jan;156(1):45-53. doi: 10.1016/j.ygyno.2019.10.001. Epub 2019 Dec 10. Gynecol Oncol. 2020. PMID: 31836184
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.
Swain SM, Tang G, Geyer CE Jr, Rastogi P, Atkins JN, Donnellan PP, Fehrenbacher L, Azar CA, Robidoux A, Polikoff JA, Brufsky AM, Biggs DD, Levine EA, Zapas JL, Provencher L, Northfelt DW, Paik S, Costantino JP, Mamounas EP, Wolmark N. Swain SM, et al. Among authors: donnellan pp. J Clin Oncol. 2013 Sep 10;31(26):3197-204. doi: 10.1200/JCO.2012.48.1275. Epub 2013 Aug 12. J Clin Oncol. 2013. PMID: 23940225 Free PMC article. Clinical Trial.
47 results